2 1 Shi Ji Jing Ji Bao Dao·2025-06-15 09:34Group 1: Company Developments - Dongyang Sunshine Pharmaceutical has submitted a second application for listing on the Hong Kong Stock Exchange, planning a zero fundraising IPO to integrate its pharmaceutical assets [1] - Benmo Technology has completed B and B+ rounds of financing, raising several hundred million RMB, which will be used for flexible motor design, enhancing delivery capabilities, and accelerating product iterations [3] - Dongguan Holdings' subsidiary has exited a private equity fund due to the fund not commencing operations, with no significant impact on its financial status [5] Group 2: Financial Performance - Dongyang Sunshine Pharmaceutical reported a revenue of 4.019 billion RMB and a net profit of 309 million RMB in 2024, with a gross margin of 76.11% [2] - Dongguan Holdings achieved a revenue of 366 million RMB and a net profit of 219 million RMB in Q1 2025 [5] - Yihua Technology reported a revenue of 620 million RMB and a net profit of 122 million RMB in Q1 2025 [9] Group 3: Awards and Recognitions - Dongyang Sunshine Pharmaceutical received the Gold Award at the 25th China Patent Awards, highlighting its commitment to innovation [4] - Entropy Technology's multi-modal biometric recognition technology has been recognized as reaching international advanced levels, showcasing its innovation capabilities [7] Group 4: Market Activities - Dongshi Environment successfully completed its first green certificate transaction, indicating progress in the environmental rights market [6] - Entropy Technology has developed various biometric recognition technologies and products, enhancing efficiency and security in complex environments [7]